Introductory

Workshop Session

Perinatal Substance Use: From Research to Practice to Public Health

Non-Presenting Organizer(s)

• 

  Vania Rudolf, MD MPH

  Junior Faculty, Addiction Recovery Services
  Swedish Medical Center

Presenter(s)

• 

  Tricia Wright, MD MS FACOG DFASAM

  Associate Professor
  University of Hawaii John A. Burns School of Medicine
• 

  Mishka Terplan, MD MPH FACOG DFASAM

  Professor
  Virginia Commonwealth University

Non-presenting author(s)

• 

  Jim Walsh, MD

  Medical Director
  Swed

Presenter(s)

• MR

  Melinda Ramage, BSN, MSN, FNP-BC

Early identification and timely treatment of substance use disorder (SUD) in pregnancy is a priority for women, families, clinicians and society. Common goals include prevention of illness progression, education regarding best care practices, and improved access to comprehensive treatment. Provision of compassionate care includes appropriate pharmacotherapy as well as safeguards against discrimination and stigmatization. Validation of this care model and approach through research will help build a stronger evidence base for effective policies and care delivery strategies in the future. As the social and health repercussions of SUD during pregnancy grow heavier, necessary interventions along the continuum of prenatal and postpartum care are gaining in urgency for programming, policy and research focus.
The panel will discuss substance use disorder treatment during pregnancy and in the postpartum period. Evidence-based management approaches for opioid use disorder, benzodiazepine use disorder, contraceptive practices, and overdose prevention will be provided. Perinatal, postpartum, neonatal, public health and research perspectives will be condensed, with the aim to translate data into a practical clinical guide.

Mishka Terplan will discuss maternal mortality and overdose prevention through a public health lens highlighting fatal and non-fatal postpartum overdose in relationship to pharmacotherapy, and provide suggestions for improving postpartum and lifecourse care.

Hendree Jones will present research data on contraception practices and address induction techniques for treating pregnant and parenting women with buprenorphine.

Tricia Wright will discuss buprenorphine dosing in pregnancy and beyond, with focus on pharmacokinetics and evidence-based recommendations in the prenatal and postpartum care.

Vania Rudolf and Jim Walsh will address challenges and practical considerations for benzodiazepine use disorder and summarize treatment benefits for optimizing maternal and neonatal outcomes.

 

Learning Objectives:

• Upon completion, participants will be able to identify current national data, trends and significant gaps in access to care for pregnant and parenting women with substance use disorder.
• Upon completion, participants will gain knowledge of maternal mortality, postpartum overdose and appreciate ways to improve lifecourse care. They'll identify practical considerations and benefits of contraception practices.
• Upon completion, participants will be able to understand buprenorphine induction and pharmacokinetics. They will be able to summarize recommendations for benzodiazepine use disorder to optimize maternal and neonatal outcomes.